0001666071false00016660712023-12-192023-12-19

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 19, 2023
 
cardlytics_logoa30.jpg
CARDLYTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware001-3838626-3039436
(State or other jurisdiction of
incorporation or organization)		(Commission
File Number)		(I.R.S. Employer
Identification No.)
675 Ponce de Leon Avenue NE, Suite 6000AtlantaGeorgia30308
(Address of principal executive offices, including zip code)
(888)798-5802
(Registrant's telephone, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
Title of each classTrading symbolName of each exchange on which registered
Common StockCDLXThe Nasdaq Stock Market LLC
 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
 ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


ITEM 8.01 OTHER EVENTS
On December 14, 2023, Cardlytics UK Limited, a wholly owned subsidiary of Cardlytics, Inc., renewed its Spending Rewards Agreement with Lloyds Bank Plc ("Lloyds"), pursuant to which Cardlytics UK Limited agreed to continue to provide its offers program to Lloyds and Lloyds customers through December 31, 2026. Cardlytics UK Limited will continue to share revenue that it generates from the sale of advertising within the Lloyds digital channels with Lloyds.






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 Cardlytics, Inc.
   
Date:December 19, 2023By:/s/ Alexis DeSieno
  Alexis DeSieno
  
Chief Financial Officer
(Principal Financial and Accounting Officer)


v3.23.4
Document and Entity Information
Dec. 19, 2023
Entity Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 19, 2023
Entity Registrant Name CARDLYTICS, INC.
Entity Registrant Name CDLX
Entity Central Index Key 0001666071
Entity Incorporation, State or Country Code DE
Entity File Number 001-38386
Entity Tax Identification Number 26-3039436
Entity Address, Address Line One 675 Ponce de Leon Avenue NE, Suite 6000
Entity Address, City or Town Atlanta
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30308
City Area Code (888)
Local Phone Number 798-5802
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Title of 12(b) Security Common Stock
Security Exchange Name NASDAQ
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Grafico Azioni Cardlytics (NASDAQ:CDLX)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Cardlytics
Grafico Azioni Cardlytics (NASDAQ:CDLX)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Cardlytics